SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapy with drugs such as SU5416 may stop the growth of cervical
cancer by stopping blood flow to the tumor.
PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have
persistent or recurrent cervical cancer.